PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

With five products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs.

LATEST NEWS

  • BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping...  MORE >
  • BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping...  MORE >
  • BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study...  MORE >